Valeant announces Q2 revenue growth

Valeant Pharmaceuticals reported total revenue of $2.7 billion for the second quarter of 2015, a 34% increase over the same period a year before, according to a press release.“We once again exceeded our guidance and delivered our fourth consecutive quarter of greater than 15% organic growth,” J. Michael Pearson, chairman and CEO, said in the release. “[The results] were driven by outperformance in our U.S. businesses, strong results in certain emerging markets and outstanding starts to both the Salix and Dendron acquisitions. In addition, we have signed eight new transactions (Read more...)